Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. - Wikidata - awgldk - TriplyDB

Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.

Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.

http://www.wikidata.org/entity/Q33654911

about

Vaccines against malaria Advances and challenges in malaria vaccine development Use of massively parallel pyrosequencing to evaluate the diversity of and selection on Plasmodium falciparum csp T-cell epitopes in Lilongwe, Malawi Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system Vaccines for malaria: how close are we?Malaria Parasites: The Great Escape Absolute Quantification of the Host-To-Parasite DNA Ratio in Theileria parva-Infected Lymphocyte Cell Lines Measurement of the plasma levels of antibodies against the polymorphic vaccine candidate apical membrane antigen 1 in a malaria-exposed population Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors Diversity of T cell epitopes in Plasmodium falciparum circumsporozoite protein likely due to protein-protein interactions.Differing patterns of selection and geospatial genetic diversity within two leading Plasmodium vivax candidate vaccine antigens.Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.A molecular epidemiological study of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in Africa Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications.Distinct patterns of diversity, population structure and evolution in the AMA1 genes of sympatric Plasmodium falciparum and Plasmodium vivax populations of Papua New Guinea from an area of similarly high transmission FungalRV: adhesin prediction and immunoinformatics portal for human fungal pathogens.The Jeremiah Metzger lecture: new additions to the toolbox for global malaria eradication.Strategies for designing and monitoring malaria vaccines targeting diverse antigens Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine Disease progression in Plasmodium knowlesi malaria is linked to variation in invasion gene family members Multiple antigen peptide vaccines against Plasmodium falciparum malaria Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria.Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.Blood stage vaccines for Plasmodium falciparum: current status and the way forward.Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria.Global Population Structure of the Genes Encoding the Malaria Vaccine Candidate, Plasmodium vivax Apical Membrane Antigen 1 (PvAMA1).Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.Seroreactivity to a large panel of field-derived Plasmodium falciparum apical membrane antigen 1 and merozoite surface protein 1 variants reflects seasonal and lifetime acquired responses to malaria.No recent adaptive selection on the apyrase of Mediterranean Phlebotomus: implications for using salivary peptides to vaccinate against canine leishmaniasis.A field trial to assess a blood-stage malaria vaccine.Genetic diversity and population structure of genes encoding vaccine candidate antigens of Plasmodium vivax.Evolution of the Transmission-Blocking Vaccine Candidates Pvs28 and Pvs25 in Plasmodium vivax: Geographic Differentiation and Evidence of Positive Selection A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens.Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens.Pooled Amplicon Deep Sequencing of Candidate Plasmodium falciparum Transmission-Blocking Vaccine Antigens.

P2860

Q17485685-9CA98BC4-19B9-4715-9878-3D47CE44F930 Q21032463-385B0C62-9663-4FA5-A8F8-F7D7B225291D Q24617275-2BE859D2-74B0-4D58-9F12-C838E29A2CA4 Q26700012-BDBD55F9-1685-43CA-9708-3C917D19B768 Q27024344-05CEE5AF-FD4D-453D-839C-E2A77B083B6C Q28080325-AA7778AD-17F8-4EC9-99CF-72DC6B802E37 Q28603519-8539022A-742C-41F7-A4E8-2B150DD3B5DC Q28730794-A84B18D8-2BE0-46C4-8231-5F3F06BC3B68 Q28731894-E8FB8A0B-1011-424E-9EA2-8D996C1E084A Q30430387-C11BAF88-A54E-4419-8100-9DEB2EF5F00E Q30439881-782C2830-84EA-4805-AB2E-4136509E2524 Q33530106-9CC8948F-9635-4A10-95AE-938C8295B891 Q33828802-9BE36A0E-2C5B-472B-851E-1FB66BB1325F Q33846126-D37D780E-0DDA-400F-B3D4-B8592C41D8C8 Q33859217-CAB1585F-BBD1-4950-90D5-FE01BE52C6C4 Q33874270-CEAA6639-C8A2-402D-9AF0-74788E9DBB32 Q33957657-B6DEEEE6-57F0-42B8-9C08-ABD559993DC5 Q33959038-447DEB2A-33FC-4259-9833-3036DF030542 Q34011922-B43F224C-5101-4420-A305-E23F77C8A779 Q34046712-0FC05991-21BA-448D-BABD-928F4320694B Q34290800-67DF0B54-F7A6-4406-B4AD-7CE092323F03 Q34290806-64EFF001-4256-4802-8537-0D0FBD5ABBD5 Q34416904-AD691AC8-DD51-4A5A-9759-4DA3EE6ED067 Q34441098-E17DB881-B933-4E31-8F87-2DD61A39D9E1 Q34507190-EEE1C4E5-3776-42AE-9D16-4256C6D47674 Q34596157-5FB029C9-4D23-4ADD-A950-19F203B999B3 Q34663978-16002921-E2D6-43F9-9C99-2FDA972127D9 Q34827195-A079C0E0-6B41-423E-B5E9-795CC2873647 Q35037036-A7CF2DEB-0D87-4DEB-80E4-0016C7C23D3F Q35048336-C898DF2D-CE55-43F7-83EF-F6994C393C9A Q35079832-27BB01F0-AB1A-4462-8A0E-01B63B534BF5 Q35140646-5672345F-2944-4875-9861-DC066F28E4C8 Q35539678-89C87C15-0288-4301-AB6E-B9124EA78690 Q35622737-9097917F-6EBC-405C-B6D7-8737FA3669AA Q35898837-ED847F05-2C43-4CD5-86D9-3530DE09AEB3 Q36062237-03F780A6-B0EB-4DCF-926E-2CAFE05D59E9 Q36141540-F3F85EA2-E29F-4953-999C-2E1EE5F3A163 Q36304234-0D71E9EE-855D-4B97-A36E-BBE93AAAB2F3 Q36384456-AE0678D9-335E-4D49-BDC8-135597C88EB6 Q36455757-5A02674A-5CA9-403B-85DB-FDDE49EF1B23

P2860

Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.

http://www.wikidata.org/entity/Q33654911

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Extreme polymorphism in a vacc ...... tions for vaccine development.

@ast

Extreme polymorphism in a vacc ...... tions for vaccine development.

@en

type

label

Extreme polymorphism in a vacc ...... tions for vaccine development.

@ast

Extreme polymorphism in a vacc ...... tions for vaccine development.

@en

prefLabel

Extreme polymorphism in a vacc ...... tions for vaccine development.

@ast

Extreme polymorphism in a vacc ...... tions for vaccine development.

@en

P1433

Q33654911-712560FA-7F79-4DB2-9131-63C25E036995

P1476

Q33654911-0CB87761-29E8-49F7-882D-46D330DD7A61

P2093

Q33654911-062DF841-CAD4-459C-9B1C-24D184541190

Q33654911-1A6C3575-CC8E-4AAF-93D5-AFCB5843D810

Q33654911-209BAEDC-61E7-4C6D-B81C-E39FC5D82FAC

Q33654911-83D562A0-AA0C-4779-9557-2236E58A71CC

Q33654911-CD05118C-67F9-4523-A46D-FF571E554BC2

Q33654911-ED94063A-E9F7-448A-9E0F-9A44C6FC4D31

P2860

Q33654911-0085C837-41D3-46F0-A66F-98CDB9D5402F

Q33654911-062B718D-2B1B-4EBB-A2BE-4EB965A69BBD

Q33654911-06DF0870-DF14-4FCD-8471-D6465140CAA8

Q33654911-07526997-33EF-44A8-A048-614E1724551D

Q33654911-0A32B291-B74D-4E76-B3E5-F645DF6C740F

Q33654911-0DDC0041-FA02-4E3C-943F-D633EFCE7469

Q33654911-17EB2843-F6E8-44FE-AFAF-0FEF167EF387

Q33654911-1D42A696-8F3F-4197-B6C0-EE8F83B22374

Q33654911-1D76E67A-9BC8-4327-8890-E9318667F6CE

Q33654911-2211C578-7497-4093-A995-027323945D34

P304

Q33654911-89DB5390-2983-4A7C-A0F7-F25BF6ABA408

P31

Q33654911-876D67C0-4449-4672-B9D3-3FBC877D4DAF

P356

Q33654911-27552136-4463-46CF-8B5A-DCFAE65C0FE1

P407

Q33654911-7E776E09-2D4F-42E8-B1BF-D008B272FE3C

P433

Q33654911-41733D57-C827-43E6-B653-5CDC207BB456

P478

Q33654911-9BA9B72E-E1BD-47A0-9E99-BEC9BD95E9C3

P50

Q33654911-4CF70C19-E23C-42FC-AC34-58F7AC2FBD3B

Q33654911-5BFDDB77-011F-4270-B524-9841A5DF9466

Q33654911-768AA20B-8B65-4FE5-8AF0-AC47CC2B65D1

Q33654911-AB1A8EB7-FB5D-4C48-955E-54AD86DD7D17

Q33654911-BEFE2769-0E5A-462A-B163-269B454CDC80

Q33654911-E48058C6-8CEA-401A-B6F4-91BF8B97332F

P577

Q33654911-46047EBC-1CF4-4A86-8593-A3511B44A6FF

P5875

Q33654911-A2D348E9-09CF-459C-822A-141365945AF2

P698

Q33654911-BD98564D-1FD2-4F79-9017-C15ED19DB7DF

P921

Q33654911-029801BF-D963-4AD4-92D5-B373BF4E33F7

P932

Q33654911-3F654654-ADB7-429E-B2A0-5A863ED01DCE

P356

SCITRANSLMED.3000257

P1433

Science Translational Medicine

P1476

Extreme polymorphism in a vacc ...... tions for vaccine development.

@en

P2093

Adrian H Batchelor

http://www.w3.org/2001/XMLSchema#string

Amed Ouattara

http://www.w3.org/2001/XMLSchema#string

Ananias A Escalante

http://www.w3.org/2001/XMLSchema#string

Karim Traoré

http://www.w3.org/2001/XMLSchema#string

Michael P Cummings

http://www.w3.org/2001/XMLSchema#string

Shannon L Takala

http://www.w3.org/2001/XMLSchema#string

P2860

Inference of population structure using multilocus genotype data

Integral membrane protein located in the apical complex of Plasmodium falciparum

Simple statistical models predict C-to-U edited sites in plant mitochondrial RNA

Few amino acid positions in rpoB are associated with most of the rifampin resistance in Mycobacterium tuberculosis

Structure of the Malaria Antigen AMA1 in Complex with a Growth-Inhibitory Antibody

Relating amino acid sequence to phenotype: analysis of peptide-binding data.

Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial.

Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali.

Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial

ama1 genes of sympatric Plasmodium vivax and P. falciparum from Venezuela differ significantly in genetic diversity and recombination frequency.

P304

2ra5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3000257

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Abdoulaye A. Djimde

Christopher V Plowe

Mahamadou A. Thera

Ogobara K Doumbo

Drissa Coulibaly

Amadou Niangaly

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41467089

http://www.w3.org/2001/XMLSchema#string

P698

20165550

http://www.w3.org/2001/XMLSchema#string

P921

P932

2822345

http://www.w3.org/2001/XMLSchema#string